Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Sept. 8 — The FDA will hold two workshops to get stakeholder input about next-generation sequencing (NGS) and how it can help advance precision medicine, two agency officials said Sept. 8 in an FDA Voice blog post.
The workshops will focus on analytical performance evaluation of NGS diagnostic tests and challenges in clinical validation of these tests.
The FDA wrote that the workshops are part of President Obama’s Precision Medicine Initiative, which envisions a day when the genetic, environmental and lifestyle differences between people will be used to customize the health care they receive.
Many efforts toward achieving this goal, including NGS, have focused on analyzing and interpreting a person’s unique genetic makeup, including the identification of genetic alterations that may affect his or her health, the FDA said.
The article, “FDA Taking Genomic Testing to the Next Level,” was written by Adam C. Berger, senior staff fellow on the personalized medicine staff at the Center for Devices and Radiological Health's Office of In Vitro Diagnostics and Radiological Health, and Zivana Tezak, the CDRH's associate director for science and technology.
NGS refers to the sequencing of millions of small fragments of DNA at the same time, creating a massive pool of data that can be used for medical diagnostics. Berger and Tezak wrote that the FDA is developing regulatory strategies for NGS-based clinical tests to ensure that these tests provide accurate, reproducible and meaningful results relevant to someone’s medical condition while continuing to foster innovation.
The first of the workshops, titled “Standards-Based Approach to Analytical Performance Evaluation of Next Generation Sequencing In Vitro Diagnostic Tests,” will be held Nov. 12 at the FDA White Oak campus in Silver Spring, Md.
It will focus on analytical performance evaluation standards, including potential ways to develop them, which can be used by test developers to ensure that their tests produce accurate and reliable results.
The second workshop, titled “Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants,” will be held Nov. 13 at the same location.
“A single company, lab, or institution is unlikely to have enough information to definitively determine the clinical importance of test results,” Berger and Tezak wrote. “The aggregation of clinical information in curated databases will create a 'data commons' that could serve as a reliable source of scientific evidence that test developers could use to demonstrate that NGS test results are relevant to a person’s disease or outcome.”
The workshop will highlight how scientists, patient groups and private industry can work together to develop high-quality, curated clinical databases of genomic information that associate specific genetic changes with various diseases, such as cardiovascular disease or diabetes.
In advance of these workshops, the authors wrote, the FDA will release additional discussion papers informed by public input, which also will include some general questions for stakeholder consideration.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Lee Barnes at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)